Public Health Impact and Cost-Effectiveness of 2-Dose vs 1-Dose Human Papillomavirus Vaccination Regimen in Saudi Arabia
Journal of Health Economics and Outcomes Research · 23.04.2026 · 13 (1)
DOI: 10.36469/001c.160028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Health Economics and Outcomes Research, online erschienen am 23.04.2026. Verfasst von Abdullah M Assiri und 8 weiteren Autor:innen. Beteiligte Einrichtung: Deputyship of Population Health Ministry of Health, Riyadh, Saudi Arabia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The Saudi Food and Drug Authority recently registered a 9-valent human papillomavirus (HPV) vaccine, which provides broader protection than the existing 4-valent vaccine against genital warts and various cancers. A single-dose protocol vs a 2-dose protocol has been considered as an option for girls aged 9 to 14 and 15 to 20 years in the Kingdom of Saudi Arabia (KSA).
Objective
To assess cost-effectiveness and health outcomes associated with 2-dose vs 1-dose 9-valent HPV (9vHPV) vaccination in the KSA.
Methods
A dynamic transmission model was used to assess public health impact and incremental cost-effectiveness ratio (ICER) of a 2-dose compared with a 1-dose 9vHPV program. Costs (2023 SAR) and quality-adjusted life-years (QALY) were discounted at 3%. Vaccination coverage was estimated using the Ministry of Health school-based program. Scenario analyses considered higher cervical cancer incidence and higher 1-dose vaccine effectiveness.
Results
A 2-dose vs a 1-dose 9vHPV vaccine prevents 13 700 additional cases of HPV-related diseases over a time horizon of 100 years. Furthermore, the model yields an ICER of SAR 30 400/QALY gained. Under scenarios of higher cervical cancer incidence and higher 1-dose vaccine effectiveness, ICERs are SAR 17 400/QALY and SAR 83 200/QALY, respectively. For the scenario with higher cervical cancer incidence (ie, 6.1 per 100 000 women), the 2-dose program achieves cervical cancer elimination within a median time of 54 years, whereas the 1-dose program takes more than 100 years. In sensitivity analyses, the ICER remains below 1×GDP per capita (SAR 129 000).
Conclusions
A 2-dose program shows a positive impact in terms of public health and cost-effectiveness compared with a 1-dose program.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Deputyship of Population Health Ministry of Health, Riyadh, Saudi Arabia.
- Outcomes Research, Eastern Europe Middle East and Africa, MSD, Puteaux, France.
- Health Economic and Decision Sciences, MSD Switzerland, Lucerne, Switzerland.
- MSD, France, Puteaux, France.
- 4Health Economics and Outcomes Research, Gulf Cooperation Council, MSD Scientific Office, Riyadh, Saudi Arabia.
- Medical Affairs Gulf Cooperation Council, MSD Scientific Office, United Arab Emirates.
ORCID-Profile: Carole Mamane
Zitieren
APA
Assiri, A. M., Mamane, C., Ugrekhelidze, D., Lévy-Bachelot, L., Alserehi, H. A. M., Albassam, G., Bassyouni, A. S., Malik, T. M., & Daniels, V. (2026). Public Health Impact and Cost-Effectiveness of 2-Dose vs 1-Dose Human Papillomavirus Vaccination Regimen in Saudi Arabia. Journal of Health Economics and Outcomes Research, 13(1). https://doi.org/10.36469/001c.160028
Vancouver
Assiri AM, Mamane C, Ugrekhelidze D, Lévy-Bachelot L, Alserehi HAM, Albassam G, et al. Public Health Impact and Cost-Effectiveness of 2-Dose vs 1-Dose Human Papillomavirus Vaccination Regimen in Saudi Arabia. Journal of Health Economics and Outcomes Research. 2026;13(1). doi:10.36469/001c.160028
BibTeX
@article{Assiri2026,
author = {Assiri, Abdullah M and Mamane, Carole and Ugrekhelidze, Dzhumber and Lévy-Bachelot, Laurie and Alserehi, Haleema A M and Albassam, Ghadah and Bassyouni, Ahmed S and Malik, Tufail M and Daniels, Vincent},
title = {Public Health Impact and Cost-Effectiveness of 2-Dose vs 1-Dose Human Papillomavirus Vaccination Regimen in Saudi Arabia},
journal = {Journal of Health Economics and Outcomes Research},
year = {2026},
volume = {13},
number = {1},
doi = {10.36469/001c.160028}
}
EUVIMED